Doctor-led longevity and preventive healthcare startup Vytalyou has secured Rs 9 crore in a pre-Series A funding round from investors Chetan Jain of Pharma Dose and Ratan Jain of Venus Industries. Announced on September 30, 2026, the investment values the company at approximately Rs 33 crore.
Founded in 2025 by Chirantan Bose and Preetesh Bhandari and headquartered in Mumbai, Vytalyou focuses on preventive healthcare and longevity-driven medical services. The fresh capital will be used to scale its network of Incremental Lifestyle Clinics across Mumbai, strengthening its presence in the preventive healthcare and longevity segment.
The startup combines diagnostic assessments with personalised health interventions and medically supervised treatment plans. Its services span pathology, radiology, cardio-respiratory evaluations, body composition analysis, genetic and cancer screening, gut microbiome assessments, personalised IV therapies, regenerative healthcare interventions and non-invasive pain management for chronic musculoskeletal conditions. The company says it has served nearly 1,000 clients since launching its first centre — around half through direct walk-ins and the rest through referrals and word of mouth — and plans to expand to 10 locations across India over the coming years.
Vytalyou is riding one of 2026's clearest healthtech waves: longevity. Earlier this year, Biopeak raised $2.7 million in follow-on funding, Cent (co-founded by Practo's Shashank ND) secured about $5 million for AI-driven early detection, Elevate Now raised Rs 18 crore in seed funding, and Decode Age closed a Rs 14.48 crore pre-Series A.
Why it matters for founders
Longevity is becoming healthtech's most fundable theme: the rounds keep landing because the customer is clear (affluent, health-anxious urban India) and the unit economics work (high-ticket, repeat-visit clinics). If you're building in preventive health, the Vytalyou playbook — clinic-led, walk-in plus referral growth, then scale to 10 locations — is a proven fundraising narrative right now.